EUVIMEDEUVIMED entdecken
Scoping ReviewOpen Access · CC BY 4.0

Pre-clinical studies of Schistosoma mansoni vaccines: A scoping review

Emma L Houlder iD, Lucas Ferreira da Silva, Angela van Diepen, Murilo Sena Amaral, R Alan Wilson, Cornelis H Hokke, Meta Roestenberg, Wilfried A M Bakker

PLOS Neglected Tropical Diseases · 02.06.2025 · 19 (6) · e0012956

DOI: 10.1371/journal.pntd.0012956 ↗

Kurz gefasst

Scoping Review in der Zeitschrift PLOS Neglected Tropical Diseases, online erschienen am 02.06.2025. Verfasst von Emma L Houlder und 7 weiteren Autor:innen. Beteiligte Einrichtung: Leiden University Center for Infectious Diseases, Leiden University Medical Center, Leiden, The Netherlands. Hauptthemen laut MEDLINE: Schistosoma mansoni, Schistosomiasis mansoni, Vaccines. Die Arbeit wurde bisher 11-mal zitiert (Crossref) und nennt 156 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: European Union’s Horizon 2020 research and innovation programme, European Union, Conselho Nacional de Desenvolvimento Científico e Tecnológico (CNPq).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Schistosomiasis is caused by infection with worms of the genus Schistosoma including S. mansoni . Over 200 million people are infected, sterile immunity does not naturally develop, and no vaccine is available. This could be a critical tool to achieve control and elimination. Numerous candidates have been tested in pre-clinical models, but there is not yet an approved vaccine. Methodology/Principal Findings We conducted a scoping review using a keyword search on Web of Science and a MeSH term search on PubMed. Articles were screened and included if they tested a defined vaccine candidate in a pre-clinical protection assay against S. mansoni between 1994–2024. Vaccine formulation, study design, and efficacy parameters from all articles were extracted. This data was summarised graphically, with the influence of different parameters appraised. A total of 141 candidate antigens were tested in 108 articles over the last 30 years, with most antigens tested only once and three (Sm-CatB, Sm-p80, and Sm-14) tested over 20 times. The median protective efficacy against worms was 35%. 10 antigens achieved over 60% efficacy, and only two (Sm-p80 and Sm-CatB) over 90%. Large variations in efficacy were observed with all repeatedly tested antigens, likely attributable to differing formulations and study designs. The effect of these varying parameters on the resultant efficacy was evaluated.

Conclusions

A few vaccine candidates have achieved promising efficacy in pre-clinical studies. Most vaccines tested however have efficacy that falls short of that required for an impactful schistosomiasis vaccine. The diversity in study designs makes comparing vaccine targets a challenge. Use of consistent and optimized vaccine formulation (including adjuvant and platform) and study design parameters is critical to expedite the development of a schistosome vaccine.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Schistosoma mansoniSchistosomiasis mansoniVaccinesAnimalsAntigens, HelminthHumans

Substanzen

Antigens, HelminthVaccines

Autor:innen und Institutionen

  • Leiden University Center for Infectious Diseases, Leiden University Medical Center, Leiden, The Netherlands.
  • Harvard Medical School, Boston, Massachusetts, United States of America.
  • Laboratório de Ciclo Celular, Instituto Butantan, São Paulo, Brazil.
  • York Biomedical Research Institute, Department of Biology, University of York, York, United Kingdom.
  • Batavia Biosciences B.V., Bioscience Park Leiden, Zernikedreef 16, Leiden, The Netherlands.

ORCID-Profile: Emma L Houlder

Förderung

  • European Union’s Horizon 2020 research and innovation programme
  • European Union
  • Conselho Nacional de Desenvolvimento Científico e Tecnológico (CNPq)
  • Fundação de Amparo à Pesquisa do Estado de São Paulo
  • European Health and Digital Executive Agency (HADEA)
  • H2020 Marie Skłodowska-Curie Actions
  • HORIZON EUROPE

Zitieren

APA

Houlder, E. L., da Silva, L. F., van Diepen, A., Amaral, M. S., Wilson, R. A., Hokke, C. H., Roestenberg, M., & Bakker, W. A. M. (2025). Pre-clinical studies of Schistosoma mansoni vaccines: A scoping review. PLOS Neglected Tropical Diseases, 19(6), e0012956. https://doi.org/10.1371/journal.pntd.0012956

Vancouver

Houlder EL, da Silva LF, van Diepen A, Amaral MS, Wilson RA, Hokke CH, et al. Pre-clinical studies of Schistosoma mansoni vaccines: A scoping review. PLOS Neglected Tropical Diseases. 2025;19(6):e0012956. doi:10.1371/journal.pntd.0012956

BibTeX
@article{Houlder2025,
  author = {Houlder, Emma L and da Silva, Lucas Ferreira and van Diepen, Angela and Amaral, Murilo Sena and Wilson, R Alan and Hokke, Cornelis H and Roestenberg, Meta and Bakker, Wilfried A M},
  title = {Pre-clinical studies of Schistosoma mansoni vaccines: A scoping review},
  journal = {PLOS Neglected Tropical Diseases},
  year = {2025},
  volume = {19},
  number = {6},
  pages = {e0012956},
  doi = {10.1371/journal.pntd.0012956}
}
Kostenlos starten →